Numis Securities reiterated their hold rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research report report published on Wednesday.

Several other equities research analysts also recently weighed in on HIK. Peel Hunt reissued a hold rating and issued a GBX 1,160 ($14.80) price target on shares of Hikma Pharmaceuticals in a report on Wednesday. Barclays reissued an underweight rating on shares of Hikma Pharmaceuticals in a report on Friday, August 10th. Citigroup reissued a buy rating and issued a GBX 1,675 ($21.37) price target on shares of Hikma Pharmaceuticals in a report on Tuesday, July 3rd. Finally, Jefferies Financial Group reissued a hold rating and issued a GBX 997 ($12.72) price target on shares of Hikma Pharmaceuticals in a report on Friday, May 18th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and one has given a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of GBX 1,230.70 ($15.70).

HIK opened at GBX 1,818 ($23.19) on Wednesday. Hikma Pharmaceuticals has a 1 year low of GBX 814.20 ($10.39) and a 1 year high of GBX 2,346 ($29.93).

The firm also recently declared a dividend, which will be paid on Friday, September 21st. Shareholders of record on Thursday, August 23rd will be issued a $0.12 dividend. This represents a yield of 0.53%. The ex-dividend date of this dividend is Thursday, August 23rd.

In other news, insider John J. Castellani bought 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 22nd. The stock was purchased at an average price of GBX 1,377 ($17.57) per share, with a total value of £13,770 ($17,566.02). Also, insider Sigurdur Olafsson bought 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 30th. The shares were purchased at an average cost of GBX 1,309 ($16.70) per share, with a total value of £261,800 ($333,971.17).

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products.

Featured Article: How to Invest in Growth Stocks

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.